Stock Events

Stock Events

Apollomics 

$0.02
25
-$0-20.6% Today

Statistics

Day High
0.01
Day Low
0.01
52W High
0.03
52W Low
0.01
Volume
420
Avg. Volume
0
Mkt Cap
17,427.4
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30MarExpected
Q4 2023
Q2 2024
Q1 2025
Q2 2025
Q3 2025
Next
-24
-23.67
-23.33
-23
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2022
2023
2024
0Revenue
-107.72MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow APLMW. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is a leading biopharmaceutical company focusing on discovering, developing, and delivering innovative medicines that address serious diseases, including cancer, which competes directly with Apollomics' oncology pipeline.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that offers cancer treatments and immunotherapies, directly competing with Apollomics' focus on developing novel therapeutics for oncology.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global biopharmaceutical company with a broad range of drugs and vaccines, including treatments for cancer, making it a competitor in the oncology space against Apollomics.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a multinational pharmaceutical company that produces a wide array of healthcare products, including innovative medicines for cancer, directly competing with Apollomics' cancer-focused therapies.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a pioneer in healthcare, with a strong emphasis on oncology, making it a direct competitor to Apollomics through its comprehensive cancer treatment portfolio.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including for cancer, which pits it against Apollomics in the oncology market.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need, including oncology, competing with Apollomics' cancer treatments.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is one of the world's leading biotechnology companies, focusing on areas including oncology/hematology, which aligns it as a competitor to Apollomics in the cancer treatment arena.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that invents, develops, and commercializes medicines for the treatment of serious medical conditions, including cancer, making it a competitor to Apollomics.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson is a diversified healthcare giant that engages in the research and development, manufacture, and sale of a broad range of healthcare products, including oncology treatments, competing with Apollomics in the pharmaceutical and biotechnology market.

About

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA.
Show more...
CEO
Employees
13
Country
US
ISIN
KYG0411D1152

Listings

XNAS
US
APLM
XNAS
US
APLMW
BOATS
BOATS
APLM.BOATS

0 Comments

Share your thoughts

FAQ

What is Apollomics stock price today?▼
The current price of APLMW is $0.02 USD — it has decreased by -20.6% in the past 24 hours. Watch Apollomics stock price performance more closely on the chart.
What is Apollomics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Apollomics stocks are traded under the ticker APLMW.
Is Apollomics stock price growing?▼
APLMW stock has fallen by -10.06% compared to the previous week, the month change is a +12.6% rise, over the last year Apollomics has showed a -45% decrease.
What is Apollomics market cap?▼
Today Apollomics has the market capitalization of 17,427.4
When is the next Apollomics earnings date?▼
Apollomics is going to release the next earnings report on September 24, 2026.
What is Apollomics revenue for the last year?▼
Apollomics revenue for the last year amounts to 0 USD.
What is Apollomics net income for the last year?▼
APLMW net income for the last year is -107.72M USD.
How many employees does Apollomics have?▼
As of April 02, 2026, the company has 13 employees.
In which sector is Apollomics located?▼
Apollomics operates in the Health Care sector.
When did Apollomics complete a stock split?▼
Apollomics has not had any recent stock splits.